Hjem
Lars Andreas Akslens bilde

Lars Andreas Akslen

Professor, Leder for CCBIO
  • E-postLars.Akslen@uib.no
  • Telefon+47 55 97 31 82
  • Besøksadresse
    Patologisk avdeling, Sentralblokka 2 etg., Haukeland Universitetssjukehus (HUS)
    evt. CCBIO, Sentralblokka 2 etg., HUS
  • Postadresse
    Postboks 7804
    5020 Bergen

Akslen er en sertifisert spesialist i kirurgisk patologi og leder forskningsgruppen Tumor Biology Research Group (etablert i 1995) ved Klinisk Institutt 1, Universitetet i Bergen. Siden 2013 har Akslen vært senterleder for Centre for Cancer Biomarkers CCBIO. Akslens gruppe og CCBIO arbeider med translasjonell kreftforskning med fokus på nye kreftmarkører og målrettet behandling og særlig mekanismer knyttet til hvordan kreftceller påvirkes av mikromiljøet i svulstene, og den betydning dette har for kreftspredning og dårlig prognose. Gruppen har prosjekter på ulike kreftformer, som brystkreft, ondartet melanom, prostatakreft og gynekologisk kreft. Gruppen kombinerer studier av humane tumorprøver med eksperimentelle celle- og dyremodeller. Det overordnede målet er å finne nye biomarkører som kan hjelpe oss til å forutse hvordan aggressive svulster vil utvikle seg og dermed bedre kunne skreddersy behandling.

Vitenskapelig artikkel
  • Vis forfatter(e) 2013. Variation in inflammatory cytokine/growth-factor genes and mammographic density in premenopausal women aged 50-55. PLOS ONE. 8 sider.
  • Vis forfatter(e) 2013. Outcome after surgery for primary hyperaldosteronism may depend on KCNJ5 tumor mutation status: a population-based study from Western Norway. Langenbeck's archives of surgery (Print). 869-874.
  • Vis forfatter(e) 2013. Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Breast Cancer Research and Treatment. 463-473.
  • Vis forfatter(e) 2013. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. Journal of Medical Genetics. 264-U82.
  • Vis forfatter(e) 2013. Lack of estrogen receptor-alpha is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. Clinical Cancer Research. 1094-1105.
  • Vis forfatter(e) 2013. Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. PLOS ONE. 9 sider.
  • Vis forfatter(e) 2013. High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma. Gynecologic Oncology. 327-334.
  • Vis forfatter(e) 2013. High phospho-stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition. Clinical Cancer Research. 2331-2341.
  • Vis forfatter(e) 2013. Expression of thyroid transcription factor-1 is associated with a basal-like phenotype in breast carcinomas. Diagnostic Pathology.
  • Vis forfatter(e) 2013. Endothelial microvascular networks affect gene-expression profiles and osteogenic potential of tissue-engineered constructs. Stem Cell Research & Therapy. 10 sider.
  • Vis forfatter(e) 2013. Dynamic contrast-enhanced MRI in endometrial carcinoma identifies patients at increased risk of recurrence. European Radiology. 2916-2925.
  • Vis forfatter(e) 2013. Bone marrow-derived Gr1(+) cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1. Cancer Discovery. 578-589.
  • Vis forfatter(e) 2013. Analysis of Latvian familial melanoma patients shows novel variants in the noncoding regions of CDKN2A and that the CDK4 mutation R24H is a founder mutation. Melanoma research. 221-226.
  • Vis forfatter(e) 2013. ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas. Modern Pathology. 428-434.
  • Vis forfatter(e) 2013. A variant in FTO shows association with melanoma risk not due to BMI. Nature Genetics. 428-432.
  • Vis forfatter(e) 2012. Tumor necrosis is a prognostic factor in thick cutaneous melanoma. American Journal of Surgical Pathology. 1477-1482.
  • Vis forfatter(e) 2012. Polymorphisms in hormone metabolism and growth factor genes and mammographic density in Norwegian postmenopausal hormone therapy users and non-users. Breast Cancer Research.
  • Vis forfatter(e) 2012. Peritoneal carcinosis in apparently benign cortisol producing adrenal adenoma >= 5 cm in diameter: the need of regular postoperative surveillance. Experimental and clinical endocrinology & diabetes. 472-476.
  • Vis forfatter(e) 2012. Microvessel proliferation by co-expression of endothelial nestin and Ki-67 is associated with a basal-like phenotype and aggressive features in breast cancer. Breast. 1-7.
  • Vis forfatter(e) 2012. Lipocalin 2 expression is associated with aggressive features of endometrial cancer. BMC Cancer. 7 sider.
  • Vis forfatter(e) 2012. KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer. British Journal of Cancer. 1997-2004.
  • Vis forfatter(e) 2012. Combination of real-time elastography and urine prostate cancer gene 3 (PCA3) detects more than 97 % of significant prostate cancers. Scandinavian Journal of Urology and Nephrology. 211-216.
  • Vis forfatter(e) 2011. Reprogramming of cell junction modules during stepwise epithelial to mesenchymal transition and accumulation of malignant features in vitro in a prostate cell model. Experimental Cell Research. 234-247.
  • Vis forfatter(e) 2010. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Medicine. 12 sider.
  • Vis forfatter(e) 2010. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. BMC Cancer. 15 sider.
  • Vis forfatter(e) 2010. Expression of aldehyde dehydrogenase a (ALDH1) is associated with basal-like markers and features of aggressive tumors in African breast cancer. British Journal of Cancer. 369-375.
  • Vis forfatter(e) 2010. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proceedings of the National Academy of Sciences of the United States of America. 1124-1129.
  • Vis forfatter(e) 2009. Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes. Clinical Cancer Research. 2302-2310.
  • Vis forfatter(e) 2009. TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. APMIS - Journal of Pathologiy, Microbiology and Immunology. 575-582.
  • Vis forfatter(e) 2009. Secondary breast cancer: a 5-year population-based study with review of the literature. APMIS - Journal of Pathologiy, Microbiology and Immunology. 762-767.
  • Vis forfatter(e) 2009. Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp-1. Proceedings of the National Academy of Sciences of the United States of America. 12115-12120.
  • Vis forfatter(e) 2009. Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer. Cancer Research. 4708-4715.
  • Vis forfatter(e) 2009. Plasma calprotectin concentrations in women with endometrial carcinoma. Gynecologic Oncology. 491-495.
  • Vis forfatter(e) 2009. Inverse correlation between PDGFC expression and lymphocyte infiltration in human papillary thyroid carcinomas. BMC Cancer. 425.
  • Vis forfatter(e) 2009. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proceedings of the National Academy of Sciences of the United States of America. 4834-4839.
  • Vis forfatter(e) 2009. Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas. Clinical Cancer Research. 1417-1427.
  • Vis forfatter(e) 2009. Importance of tumour cell invasion in blood and lymphatic vasculature among patients with endometrial carcinoma. Histopathology. 174-183.
  • Vis forfatter(e) 2009. Identification of a CDK4 R24H mutation-positive melanoma family by analysis of early-onset melanoma patients in Latvia. Melanoma research. 119-122.
  • Vis forfatter(e) 2009. Hyperoxic treatment induces mesenchymal to epithelial transition in a rat adenocarcinoma model. PLOS ONE.
  • Vis forfatter(e) 2009. Genome-wide profiling of histone H3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis. PLOS ONE. 14 sider.
  • Vis forfatter(e) 2009. Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer. Journal of Clinical Pathology. 139-146.
  • Vis forfatter(e) 2009. Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. British Journal of Cancer. 1282-1289.
  • Vis forfatter(e) 2009. Estrogen receptor β– an independent prognostic marker in estrogen receptor α and progesterone receptor-positive breast cancer? APMIS - Journal of Pathologiy, Microbiology and Immunology. 644-650.
  • Vis forfatter(e) 2009. Deoxyribonucleic acid ploidy in endometrial carcinoma: a reproducible and valid prognostic marker in a routine diagnostic setting. American Journal of Obstetrics and Gynecology. 603-607.
  • Vis forfatter(e) 2009. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clinical Cancer Research. 3484-3494.
  • Vis forfatter(e) 2008. WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence. Clinical Cancer Research. 1397-1406.
  • Vis forfatter(e) 2008. Tumor necrosis is associated with increased alphavbeta3 integrin expression and poor prognosis in nodular cutaneous melanomas. BMC Cancer. 362-372.
  • Vis forfatter(e) 2008. Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas. Genes, Chromosomes and Cancer. 175-184.
  • Vis forfatter(e) 2008. Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma research. 29-35.
  • Vis forfatter(e) 2008. Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma. British Journal of Cancer. 1662-1669.
  • Vis forfatter(e) 2008. Loss of BMI-1 expression is associated with clinical progress of malignant melanoma. Modern Pathology. 583-590.
  • Vis forfatter(e) 2008. Lesson of the Month - Independent prognostic value of the basal-like phenotype of breast cancer and associations with EGFR and candidate stem cell marker BMI-1. Histopathology. 370-380.
  • Vis forfatter(e) 2008. Hyperthermia improves the antitumour effect of metronomic cyclophosphamide in a rat transplantable brain tumour. Radiotherapy and Oncology. 435-442.
  • Vis forfatter(e) 2008. HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. International Journal of Oncology. 307-316.
  • Vis forfatter(e) 2008. GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival. American Journal of Obstetrics and Gynecology. e 1-7.
  • Vis forfatter(e) 2008. Expression of EGFR and c-kit is associated with the basal-like phenotype in breast carcinomas of African women. APMIS - Journal of Pathologiy, Microbiology and Immunology. 515-525.
  • Vis forfatter(e) 2008. Epithelial to Mesenchymal Transition of a Primary Prostate Cell Line with Switches of Cell Adhesion Modules but without Malignant Transformation. PLOS ONE.
  • Vis forfatter(e) 2008. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 8713-8717.
  • Vis forfatter(e) 2007. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 11 sider.
  • Vis forfatter(e) 2007. Frequency of the basal-like phenotype in African breast cancer. APMIS - Journal of Pathologiy, Microbiology and Immunology. 1391-1399.
  • Vis forfatter(e) 2007. ERG upregulation and related ETS transcription factors in prostate cancer. International Journal of Oncology. 19-32.
  • Vis forfatter(e) 2007. Comparison of nucleic acid targets prepared from total RNA or poly(A) RNA for DNA oligonucleotide microarray hybridization. Analytical Biochemistry. 46-58.
  • Vis forfatter(e) 2007. A Switch from E-Cadherin to N-Cadherin Expression Indicates Epithelial to Mesenchymal Transition and Is of Strong and Independent Importance for the Progress of Prostate Cancer. Clinical Cancer Research. 7003-7011.
  • Vis forfatter(e) 2006. Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Research. 3303-3309.
  • Vis forfatter(e) 2006. Role of angiogenesis in human tumor dormancy - Animal models of the angiogenic switch. Cell Cycle. 1779-1787.
  • Vis forfatter(e) 2006. Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas. American Journal of Obstetrics and Gynecology. 979-986.
  • Vis forfatter(e) 2006. Loss of p63 and cytokeratin 5/6 expression is associated with more aggressive tumors in endometrial carcinoma patients. International Journal of Cancer. 1227-1233.
  • Vis forfatter(e) 2006. Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Molecular Cancer Therapeutics. 2914-2918.
  • Vis forfatter(e) 2006. Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid. 161-175.
  • Vis forfatter(e) 2006. Expression of bFGF/FGFR-1 and vascular proliferation related to clinicopathologic features and tumor progress in localized prostate cancer. Virchows Archiv. 68-74.
  • Vis forfatter(e) 2006. Body size and thyroid cancer in two million Norwegian men and women. British Journal of Cancer. 366-370.
  • Vis forfatter(e) 2006. A model of human tumor dormancy: An angiogenic switch from the nonangiogenic phenotype. Journal of the National Cancer Institute. 316-325.
  • Vis forfatter(e) 2005. Strong expression of ID1 protein is associated with decreased survival, increased expression of ephrin-A1/EPHA2, and reduced thrombospondin-1 in malignant melanoma. British Journal of Cancer. 933-938.
  • Vis forfatter(e) 2005. Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clinical Cancer Research. 8606-8614.
  • Vis forfatter(e) 2005. Early detection of brest cancer based on gene-expression patterns in peripheral blood cells. Breast Cancer Research. R634-R644.
  • Vis forfatter(e) 2005. Early detection of breast cancer based on gene-expression patterns in peripheral blood cells. Breast Cancer Research. 634-644.
  • Vis forfatter(e) 2005. BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. Journal of Investigative Dermatology. 312-317.
  • Vis forfatter(e) 2004. Karnydanning og tumorkar som mål for kreftterapi. Tidsskrift for Den norske legeforening. 1919-1922.
  • Vis forfatter(e) 2003. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clinical Cancer Research. 5582-5588.
  • Vis forfatter(e) 2003. Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas. APMIS - Journal of Pathologiy, Microbiology and Immunology. 1011-1018.
  • Vis forfatter(e) 2003. Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. European Journal of Cancer. 438-446.
  • Vis forfatter(e) 2003. Molecular assessment of depth of myometrial invasion in stage I endometrial cancer: a model based on K-ras mutation analysis. Gynecologic Oncology. 218-25.
  • Vis forfatter(e) 2003. MSI-low, a real phenomenon which varies in frequency among cancer types. Journal of Pathology. 389-94.
  • Vis forfatter(e) 2003. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. Journal of the National Cancer Institute. 1482-85.
  • Vis forfatter(e) 2003. Benign growth of different prostate zones in aging men with slightly elevated PSA in whom prostate cancer has been excluded: a prospective study of 510 patients. Urology. 447-450.
  • Vis forfatter(e) 2002. Molecular pathogenesis and prognostic factors in endometrial carcinoma. APMIS - Journal of Pathologiy, Microbiology and Immunology. 673-689.
  • Vis forfatter(e) 2002. Loss of hMSH2 and hMSH6 expression is frequent in sporadic endometrial carcinomas with microsatellite instability: a population-based study. Clinical Cancer Research. 138-43.
  • Vis forfatter(e) 2002. Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma. Cancer. 2185-91.
  • Vis forfatter(e) 2002. Can we rely on pathologic parameters to define conservative treatment of papillary thyroid carcinoma? International Journal of Surgical Pathology. 267-272.
  • Vis forfatter(e) 2001. Expression of oestrogen and progesterone receptorss, Ki-67, p53 and BCL-2 proteins, cathepsin D, urokinase plasminogen activator and urokinase plasminogen activator-receptors in carcinomas of the female breast in an African poplation. East African Medical Journal. 360-5.
  • Vis forfatter(e) 2001. Expression and alternative splicing of c-ret RNA in papillary thyroid carcinomas. Oncogene. 885-892.
  • Vis forfatter(e) 2000. Molecular portraits of human breast tumours. Nature. 747-52.
  • Vis forfatter(e) 2000. Frequent loss of p16 protein expression and high proliferative activity (Ki-67) in malignant melanoma from black Africans. Anticancer Research. 4857-62.
  • Vis forfatter(e) 1998. Prognostic impact of morphometric nuclear grade in endometrial carcinoma. Cancer. 956-964.
  • Vis forfatter(e) 1998. Independent prognostic importance of microvessel density in endometrial carcinoma. British Journal of Cancer. 1140-1144.
  • Vis forfatter(e) 1998. Identification of high-risk patients by assessment of nuclear Ki67 expression in a prosepective study of endometrial carcinoma patients. Clinical Cancer Research. 2779-2785.
  • Vis forfatter(e) 1998. Frequent mutations of the p53 gene in cutaneous melanoma of the nodular type. International Journal of Cancer. 91-95.
  • Vis forfatter(e) 1998. Diagnostisk molekylærbiologi ved solide svulster: Thyreoideacancer. Tidsskrift for Den norske legeforening. 2199-2203.
  • Vis forfatter(e) 1998. Diagnostisk molekylærbiologi ved solide svulster - thyreoidea. Tidsskrift for Den norske legeforening. 2199-2203.
  • Vis forfatter(e) 1998. Decreased survival for nulliparous women with endometrial carcinoma. Is the relationship due to biology or behaviour? Cancer. 1328-1333.
  • Vis forfatter(e) 1997. Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. International Journal of Cancer. 138-140.
  • Vis forfatter(e) 1997. Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • Vis forfatter(e) 1997. Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • Vis forfatter(e) 1996. Thyroid carcinomas with tall-cell and columnar-cell features (letter). Current Diagnostic Pathology. 67.
  • Vis forfatter(e) 1996. Spesific TP53 gene mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Medicine. 811-814.
  • Vis forfatter(e) 1996. Relationship between mutations in the TP53 gene and De Novo resistance and early relapse following treatment with doxorubicin in patients with breast cancer. Nature Medicine. 811-814.
  • Vis forfatter(e) 1996. Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
  • Vis forfatter(e) 1996. Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; Clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
  • Vis forfatter(e) 1996. Independent prognostic importance of vascular invasion in nodular melanomas. Cancer. 1211-1219.
  • Vis forfatter(e) 1996. Incidence of thyroid cancer in New Caledonia, South Pacific, during 1985-1992 (letter). American Journal of Epidemiology. 1174.
  • Vis forfatter(e) 1996. Expression of c-erbB-3 and c-erbB-4 proteins in papillary thyroid carcinomas. Cancer Research. 1184-1188.
  • Vis forfatter(e) 1996. Aggressive thyroid carcinoma with predominant cribriform growth pattern. Pathology, Research and Practice.
  • Vis forfatter(e) 1995. Primary organ culture of non-neoplastic and neoplastic thyroid tissue multicellular spheroids. International Journal of Oncology. 1071-1078.
  • Vis forfatter(e) 1995. Primary organ culture of non-neoplastic and neoplastic thyroid tissue as multicellular spheroids. International Journal of Oncology. 1071-1078.
  • Vis forfatter(e) 1995. Primary organ culture of non-neoplastic and neoplastic thyroid tissue as multicellular spheroids. International Journal of Oncology. 1071-1078.
  • Vis forfatter(e) 1995. Oncoproteins and tumor progression in papillary thyroid carcinoma. Presence of epidermal growth factor receptor (EGF-R), c-erbB-2 protein, estrogen receptor related protein (29), p21-ras protein and proliferation indicators in relation to tumor recurrences and patient survival. Cancer. 1643-1654.
  • Vis forfatter(e) 1995. Lack of diagnostic value of DNA content and p53 immunostaining in normal, hyperplastic and neoplastic parathyroid tissue. Oncology Reports. 69-72.
  • Vis forfatter(e) 1995. Histopatologiens betydning for vurdering av kreftforekomst og kreftårsaker. Tidsskrift for Den norske legeforening. 943-946.
  • Vis forfatter(e) 1994. Ploidy and proliferative rates in carcinomas of the breast in Tanzania. East African Medical Journal. 195-198.
  • Vis forfatter(e) 1994. Kreft i skjoldbruskkjertelen - økning i yngre årskull. Kreftnytt. 4-6.
  • Vis forfatter(e) 1994. Increase of endo-and exo-peptidases in thyroid tumors. Oncol Rep. 953-956.
  • Vis forfatter(e) 1994. Etiologiske og patobiologiske aspekter ved malignt melanom. Tidsskrift for Den norske legeforening. 908-911.
  • Vis forfatter(e) 1993. Thyroid cancer in children in Norway 1953-1987. European Journal of Cancer. 365-366.
  • Vis forfatter(e) 1993. Prognostic importance of histologic grading in papillary thyroid carcinoma. Cancer. 2680-2685.
  • Vis forfatter(e) 1993. Demonstration of a TGF-_a-EGF receptor autocrine loop and c-myc protein overexpression in papillary thyroid carcinomas. International Journal of Cancer. 37-43.
  • Vis forfatter(e) 1992. Expression of p53 protein in cutaneous melanoma. International Journal of Cancer. 13-16.
  • Vis forfatter(e) 1991. Thyroid carcinoma. Results from a uniform surgical strategy 1971-1985. Acta Chirurgica Scandinavica. 521-526.
  • Vis forfatter(e) 1991. Survival and cause of death in thyroid cancer: A population-based study of 2479 cases from Norway. Cancer Research. 1234-1241.
  • Vis forfatter(e) 1991. Squamous cell carcinoma of the urinary bladder. Scandinavian Journal of Urology and Nephrology. 275-276.
  • Vis forfatter(e) 1991. Radical radiation treatment of invasive and locally advanced bladder carcinoma in elderly patients. British Journal of Urology. 61-69.
  • Vis forfatter(e) 1991. Periodicity in metastatic tumour growth demonstrated in human liver at autopsy. Invasion Metastasis. 58-64.
  • Vis forfatter(e) 1990. Provocation of thyroid neoplasms in female Wistar rats fed n-3 or n-6 fatty acids in the feed. Thyroidology. 1-3.
  • Vis forfatter(e) 1989. Lifestyle and mortality among Norwegian men. Preventive Medicine. 433-443.
Vitenskapelig foredrag
  • Vis forfatter(e) 2016. Molecular subtypes of breast cancer: long-term incidence trends and prognostic differences.
  • Vis forfatter(e) 2016. FGD5 amplification in breast cancer patients is associated with tumour proliferation and a poorer prognosis.
  • Vis forfatter(e) 2013. Molekylære subtyper og overlevelse ved brystkreft.
  • Vis forfatter(e) 2013. Molekylære subtyper og overlevelse ved brystkreft.
  • Vis forfatter(e) 2012. Multimodal imaging for suspected recurrent differentiated thyroid cancer (DTC): FDG-PET-CT, I-131-SPECT-CT, ultrasound (US) and US-guided fine needle biopsy (FNB).
  • Vis forfatter(e) 2011. Multimodal imaging for diagnosis and treatment of recurrent differentiated thyroid cancer (DTC)FDG-PET-CT, contrast-enhanced CT (CE-CT), I-131-SPECT-CT, ultrasound (US) and US-guided fine needle biopsy (FNB).
  • Vis forfatter(e) 2011. In vivo Dynamic Contrast Enhanced MRI & Histopathological Assessment of Tumor Angiogenesis in Luminal-like and Basal-like Breast Cancer Xenografts.
  • Vis forfatter(e) 2011. FDG-PET-CT, I-131-SPECT-CT, ultrasound (US) and US-guided fine needle biopsy (FNB) for recurrent differentiated thyroid cancer (DTC).
  • Vis forfatter(e) 2011. Early vascular response to bevacizumab treatment measured by DCE-MRI in breast cancer xenografts.
  • Vis forfatter(e) 2011. DCE-MRI for early therapy monitoring of anti-angiogenic therapy.
  • Vis forfatter(e) 2010. Real time elastografi ved cancer prostatae.
  • Vis forfatter(e) 2010. Preliminære resultater av PCA3 måling i urin hos pasienter med cancer prostatae.
  • Vis forfatter(e) 2010. Multimodal imaging of differentiated thyroid cancer: FDG-PET-CT, I-131-SPECT-CT and ultrasound.
  • Vis forfatter(e) 2010. In vivo magnetic resonance imaging and histopathological assessment of tumor microenvironment in luminal-like and basal-like breast cancer xenografts.
  • Vis forfatter(e) 2010. Er preoperativ MR-prostata nyttig for å avklare korrekt T-stadium forut for kirurgi?
  • Vis forfatter(e) 2010. Er MR-prostata nyttig for å avklare videre oppfølgningsbehov hos pasienter med 2 eller flere negative biopsiserier?
  • Vis forfatter(e) 2009. Genome-wide profiling of histone H3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis.
  • Vis forfatter(e) 2009. EMT Promotes Malignant Transformation of Prostate Epithelial Cells in Culture.
  • Vis forfatter(e) 2008. Polycomb group target genes and bivalent H3K4 & K27me3 modifications in human embryonic cells were enriched among dysregulated genes in prostate cancer.
  • Vis forfatter(e) 2008. Epithelial to mesenchymal transition of a primary, immortalized prostate cell line is associated with gene expression switches of entire cell attachment modules.
  • Vis forfatter(e) 2007. Functional oncogenomics and epigenomics analysis of prostate cancer.
  • Vis forfatter(e) 2007. Detection of TMPRSS2:ERG translocations in the urine of prostate cancer patients and identification of ERG target genes.
  • Vis forfatter(e) 2006. Global gene expression analysis of transcription factors in prostate cancer and cell lines.
  • Vis forfatter(e) 2006. ERG upregulation and related transcription factors in prostate cancer.
  • Vis forfatter(e) 2004. Gene expression profiling in prostate cancer refined by pairwise comparisons of cDNA microarrays from benign and malignant tissue.
  • Vis forfatter(e) 2004. Gene expression profiles in prostate cancer: identification of upregulated SIM2 gene validated in archival tissue, relation to histological grading and prognosis.
  • Vis forfatter(e) 2003. Mutation analysis of the RAS-RAF pathway in pancreatic adenocarcinomas and malignant melanomas.
  • Vis forfatter(e) 2003. Global analysis of gene expression and regulatory patterns in urogenital tumours using DNA microarrays.
  • Vis forfatter(e) 2003. Global analysis of gene expression and regulatory patterns in cancer.
  • Vis forfatter(e) 2003. Gene expression profiling in prostate cancer: cluster analysis and association with tumor differentation.
  • Vis forfatter(e) 2003. Gene expression profiling in prostate cancer: Cluster analysis and association with tumor differentiation.
  • Vis forfatter(e) 2003. Gene expression profiling in prostate cancer.
  • Vis forfatter(e) 2003. DNA microarray studies of human cancer - pitfalls and outlook.
  • Vis forfatter(e) 2003. Comparison of DNA microarray and real time quantitative PCR for quantitation of gene expression of selected genes in prostate cancer.
  • Vis forfatter(e) 2002. Cancer mammae behandlet med brystbevarende kirurgi ved Haukeland sykehus 1984-1995.
  • Vis forfatter(e) 2001. Prognostisk betydning av angiogenese (microvessel density - MVD) og proliferasjonsmarkøren Ki-67 ved lokalisert prostatacencer.
  • Vis forfatter(e) 1999. Prognostic importance of microvessel density (MVD) in clinically localized prostate cancer.
  • Vis forfatter(e) 1998. Prognostic importance of microvessel density (MVD) in clinically localized prostate cancer.
  • Vis forfatter(e) 1998. Profylaktisk thyroidectomi hos barn - initial erfaring.
  • Vis forfatter(e) 1998. Malignt melanom på hender.
  • Vis forfatter(e) 1998. Malignant melanoma of the hand. A 25-year clinico-pathological study.
  • Vis forfatter(e) 1997. Independent prognostic importance of microvessel density in endometrial carcinoma. [poster].
  • Vis forfatter(e) 1989. Mortality form ischemic heart disease related to life-style differences among Norwegian men (Abstract).
Vitenskapelig antologi/Konferanseserie
  • Vis forfatter(e) 2017. Biomarkers of the Tumor Microenvironment: Basic Studies and Practical Applications. Springer.
Sammendrag/abstract
  • Vis forfatter(e) 2013. Proliferation markers PHH3, Ki67 and mitotic count all show significant associations with features of aggressive breast carcinomas and reduced survival. Modern Pathology. 50A-50A.
  • Vis forfatter(e) 2013. Proliferation markers PHH3, Ki67 and Mimtotic count all show significant associations with features of aggressive breast carcinomas and reduced survival. Laboratory Investigation. 50A-50A.
  • Vis forfatter(e) 2013. FOXA1 LOSS IN ENDOMETRIAL CANCER IS ASSOCIATED WITH POOR PROGNOSIS AND ER ALPHA LOSS. International Journal of Gynecological Cancer. 1 sider.
  • Vis forfatter(e) 2012. Prognostic impact of proliferation markers Ki-67, PHH3 and mitotic count in breast carcinomas. Virchows Archiv. S5-S5.
  • Vis forfatter(e) 2012. Metabolic Responses to VEGF Inhibition in Patient-derived Breast Cancer Xenografts. European Journal of Cancer. S32-S32.
  • Vis forfatter(e) 2012. Expression of hypoxia-inducible factor-1a and associations with vascular endothelial growth factor expression, high microvessel density and features of aggressive tumors in African breast cancer. Virchows Archiv. S249-S249.
  • Vis forfatter(e) 2012. Estrogen receptor a loss in endometrial carcinoma is associated with epithelial-to-mesenchymal transition and a potential for PI3Kinase inhibition. Virchows Archiv. S18-S18.
  • Vis forfatter(e) 2011. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Clinical and Experimental Metastasis. 234-235.
  • Vis forfatter(e) 2010. Prognostic importance of vascular proliferation and tumor cell invasion in blood and lymphatic vessels in endometrial carcinoma. APMIS - Journal of Pathologiy, Microbiology and Immunology. 248-248.
  • Vis forfatter(e) 2010. Multimodal imaging of differentiated thyroid cancer: FDG-PET-CT, I-131-SPECT-CT and ultrasound [Abstract]. European Journal of Nuclear Medicine and Molecular Imaging. S291-S291.
  • Vis forfatter(e) 2009. Proliferation of immature tumor vessels is a novel marker of clinical progress in prostate cancer. APMIS - Journal of Pathologiy, Microbiology and Immunology. 233-233.
  • Vis forfatter(e) 2008. Vascular proliferation by Nestin/Ki-67 is a novel predictor of the clinical progress of prostate cancer. Histopathology. 276-277.
  • Vis forfatter(e) 2008. Candidate stem cell marker ALDH1 expression and relationship with BRCA-mutations and basal-like differentiation in breast carcinoma. Histopathology. 25-25.
  • Vis forfatter(e) 2007. Loss of BMI-1 expression is associated with the clinical progress of malignant melanoma. Virchows Archiv. 452-452.
  • Vis forfatter(e) 2007. Epithelial to mesenchymal transition is of strong prognostic importance in prostate cancer. Virchows Archiv. 344-344.
  • Vis forfatter(e) 2007. Basal-like phenotype is frequent in invasive breast carcinoma from Ugandan Africans and is strongly associated with a high expression of EGFR/c-Kit and features of aggressive tumors. Virchows Archiv. 137-137.
  • Vis forfatter(e) 2006. Global gene expression analysis of transcription factors in prostate cancer and cell lines. International Journal of Molecular Medicine. S27.
  • Vis forfatter(e) 2006. ERG upregulation in relation to other transcription factors in prostate cancer. NBS-nytt. 72.
  • Vis forfatter(e) 2005. Single-minded 2 homolog gene is overexpressed in prostate cancer. Virchows Archiv. 432-432.
  • Vis forfatter(e) 2005. Overexpression of ERG and SIM2 transcription factors in prostate cancer. International Journal of Molecular Medicine. S76-S76.
Vitenskapelig oversiktsartikkel/review
  • Vis forfatter(e) 2013. Malignt melanom – diagnostikk, behandling og oppfølging i Norge. Tidsskrift for Den norske legeforening. 2154-2159.
  • Vis forfatter(e) 2009. Biologic markers in endometrial cancer treatment. APMIS - Journal of Pathologiy, Microbiology and Immunology. 693-707.
  • Vis forfatter(e) 2008. Tumor-vascular interactions and tumor dormancy. APMIS - Journal of Pathologiy, Microbiology and Immunology. 569-585.

Se fullstendig oversikt over publikasjoner i CRIStin.